Goldman Sachs’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Goldman Sachs’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50,000	Closed	-$231K	–	5794
2020 Q3	$231K	Buy	+50,000	New	+$165K	﹤0.01%	4861
2018 Q2	–	Sell	-12,500	Closed	-$133K	–	6127
2018 Q1	$133K	Buy	+12,500	New	+$201K	﹤0.01%	5175
2017 Q4	–	Sell	-6,250	Closed	-$344K	–	6749
2017 Q3	$344K	Buy	6,250 +5,000	+400%	+$843K	﹤0.01%	5369
2017 Q2	$232K	Sell	1,250 -11,250	-90%	-$1.97M	﹤0.01%	5698
2017 Q1	$1.49M	Sell	12,500 -10,675	-46%	-$1.12M	﹤0.01%	4026
2016 Q4	$2.3M	Buy	23,175 +12,500	+117%	+$1.32M	﹤0.01%	3725
2016 Q3	$1.2M	Buy	+10,675	New	+$1.28M	﹤0.01%	4249

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Goldman Sachs's SIOX Position: Q1 2022 in Review

Goldman Sachs sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 17,355 shares — an estimated $22K sold.

Goldman Sachs first reported a position in SIOX in Q1 2016 and held it in 19 quarters. The position peaked at $2.25M in Q4 2016. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

Goldman Sachs reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 17,355 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $22K.
Goldman Sachs first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2016 and held it in 19 quarters.
Goldman Sachs's Sio Gene Therapies Inc. Common Stock position peaked at $2.25M in Q4 2016.
41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.